<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00021554</url>
  </required_header>
  <id_info>
    <org_study_id>295D</org_study_id>
    <secondary_id>T20-302</secondary_id>
    <nct_id>NCT00021554</nct_id>
  </id_info>
  <brief_title>T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs</brief_title>
  <official_title>A Phase III Open-Label, Randomized, Active-Controlled Study Assessing the Efficacy and Safety of T-20 (HIV-1 Fusion Inhibitor) in Combination With an Optimized Background Regimen, Versus Optimized Background Regimen Alone, in Patients With Prior Experience and/or Prior Documented Resistance to Each of the Three Classes of Approved Antiretrovirals (Nucleoside Reverse Transcriptase, Non-Nucleoside Reverse Transcriptase and Protease Inhibitors)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trimeris</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to show if a dose of T-20 added to an anti-HIV combination&#xD;
      (chosen specifically for each patient) lowers viral load by at least a certain level after 24&#xD;
      weeks as compared to an anti-HIV combination (chosen specifically for each patient) alone.&#xD;
      Another purpose is to show if the patient response to T-20 will be maintained for 48 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An OB regimen is selected to be initiated at baseline by the physician and patient. The OB&#xD;
      regimen is based on the patient's prior treatment history as well as the results from the&#xD;
      first screening visit HIV-1 genotypic and phenotypic (GT and PT) resistance testing and prior&#xD;
      GT/PT antiretroviral resistance testing (if available). Prior or current laboratory&#xD;
      abnormalities, including triglycerides and cholesterol, should also be taken into account&#xD;
      when selecting the OB regimen. Patients are stratified with respect to the following: 1)&#xD;
      screening viral load (less than 40,000 or 40,000 or more copies/ml); and 2) number of allowed&#xD;
      investigational antiretrovirals (0, 1, or 2). Patients then are randomized to receive 1 of&#xD;
      the following treatments for 48 weeks: OB regimen or OB plus T-20 regimen. Patients are seen&#xD;
      for evaluation of efficacy and safety at Weeks 1, 2, and 4, every 4 weeks through Week 24,&#xD;
      and then every 8 weeks through Week 48. In addition, efficacy only is evaluated at Weeks 6,&#xD;
      10, and 14. Patients also may be seen at additional visits during the study for plasma HIV-1&#xD;
      RNA measurements to potentially confirm virological failure.&#xD;
&#xD;
      Patients initially randomized to the OB arm who meet the criteria for virological failure and&#xD;
      who switch to OB plus T-20 after Week 8 are followed under a new (&quot;switch&quot;) schedule of&#xD;
      assessments. Patients are encouraged to change their OB regimen at the time of switch.&#xD;
&#xD;
      Patients initially randomized to the OB plus T-20 arm who meet the criteria for virological&#xD;
      failure may continue to receive OB plus T-20 if the patient and the physician feel that there&#xD;
      is sufficient benefit. Patients are encouraged to change their OB regimen after Week 8 if&#xD;
      they choose to continue on OB plus T-20 despite meeting the criteria for virological failure.&#xD;
&#xD;
      Patients on OB or OB plus T-20 arm who meet the criteria for virological failure but who do&#xD;
      not wish to either switch to T-20 (for patients initially randomized to OB arm) or continue&#xD;
      with T-20 (for patients initially randomized to OB plus T-20) are allowed to remain in the&#xD;
      study for a maximum of 1 month.&#xD;
&#xD;
      At the end of the 48 weeks of treatment, patients are allowed to participate in 1 of the&#xD;
      following treatment extensions: a) roll-over and receive OB plus T-20 (for patients receiving&#xD;
      OB alone); or b) continue taking OB plus T-20 (for patients already receiving OB plus T-20),&#xD;
      for a maximum of an additional 48 weeks (plus 4 weeks safety follow-up period), or until 12&#xD;
      weeks after commercial availability of T-20 in the country in which they are treated,&#xD;
      whichever comes first. All patients are followed for a maximum of 100 weeks from their&#xD;
      initial baseline visit date.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>525</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enfuvirtide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients may be eligible for this study if they:&#xD;
&#xD;
          -  Are HIV infected.&#xD;
&#xD;
          -  Are at least 16 years of age.&#xD;
&#xD;
          -  Have an HIV-1 RNA of at least 5,000 copies/ml.&#xD;
&#xD;
          -  Have received anti-HIV drugs for at least 3 months and/or have written records of&#xD;
             resistance to at least 1 member of each of the 3 classes of anti-HIV drugs (nucleoside&#xD;
             reverse transcriptase inhibitors [NRTIs], nonnucleoside reverse transcriptase&#xD;
             inhibitors [NNRTIs], and protease inhibitors [PIs]). Resistance to NNRTIs may not be&#xD;
             required in certain cases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Carlton Clinic</name>
      <address>
        <city>Carlton</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House General Practice</name>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent's Hosp</name>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Hosp</name>
      <address>
        <city>Herston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hosp</name>
      <address>
        <city>Prahan</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prahran Market Clinic</name>
      <address>
        <city>South Yarra</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taylors Square Clinic</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst of Tropical Medicine</name>
      <address>
        <city>Antwerpe</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Pierre</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheinische Friedrich Wilhelms Universitaet Medizinische</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Der Johann Wolfgang Goethe Universitat</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus St Georg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatskrankenhaus Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Malattie Infettive</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Malattie Infettive</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Amedeo di Savoia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natac Med Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Medical Center Utrecht</name>
      <address>
        <city>CX Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias I Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Mas</name>
      <address>
        <city>Malmoe</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Venhalsan Soder Hosp</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Hosp Basel / Med Outpatient Dept</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital cantonal / Div des maladies infectieuses</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsspital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton Gen Hosp</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Gen Hosp</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Univ Hosp</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hosp</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hosp</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ College London Med School</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Manchester Gen Hosp</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Lazzarin A, Clotet B, Cooper D, Reynes J, Arast√©h K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M; TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003 May 29;348(22):2186-95.</citation>
    <PMID>12773645</PMID>
  </reference>
  <verification_date>May 2002</verification_date>
  <study_first_submitted>July 21, 2001</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>RNA, Viral</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Viral Load</keyword>
  <keyword>pentafuside</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enfuvirtide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

